News Releases

May 10, 2022
Verve on Track to Begin Dosing HeFH Patients in New Zealand in Mid-2022 in a Phase 1 Clinical Trial with Initial Clinical Data Expected in 2023 Preparing for Submission of United Kingdom and United States Regulatory Filings for VERVE-101 in Second Half of 2022 Cash, Cash Equivalents and Marketable
April 4, 2022
Updated Sequential Dosing Data Show Administration of PCSK9 Base Editor Followed by ANGPTL3 Base Editor is Well-Tolerated in NHPs Data to be Presented Today at the American College of Cardiology 71 st Annual Scientific Session & Expo CAMBRIDGE, Mass., April 04, 2022 (GLOBE NEWSWIRE) -- Verve
Displaying 11 - 20 of 21